Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Sponsor:
Collaborator:
University of Athens
Information provided by:
Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT00306176
First received: March 22, 2006
Last updated: April 3, 2007
Last verified: April 2007
  Purpose

The aim of the present study is to investigate the influence of systemic exercise, rosiglitazone administration and combined pharmaceutical and lifestyle intervention on cardiovascular risk factors


Condition Intervention Phase
Type II Diabetes Mellitus
Drug: Rosiglitazone
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Rosiglitazone and Exercise in Patients With Type 2 Diabetes Mellitus

Resource links provided by NLM:


Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Cardiovascular risk factors alterations

Estimated Enrollment: 100
Study Start Date: January 2005
Estimated Study Completion Date: October 2006
  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Type II diabetes mellitus
  • Poor glycemic control

Exclusion Criteria:

  • Heart failure
  • Renal disease
  • Liver disease
  • Cardiovascular event
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00306176

Locations
Greece
AHEPA University Hospital of Thessaloniki
Thessaloniki, Greece, 54454
Sponsors and Collaborators
Aristotle University Of Thessaloniki
University of Athens
Investigators
Study Chair: Christos Liapis, PhD,MD University of Athens,Greece
  More Information

No publications provided by Aristotle University Of Thessaloniki

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00306176     History of Changes
Other Study ID Numbers: 1975
Study First Received: March 22, 2006
Last Updated: April 3, 2007
Health Authority: Greece: National Organization of Medicines

Keywords provided by Aristotle University Of Thessaloniki:
rosiglitazone,exercise,cardiovascular risk factors

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Rosiglitazone
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014